Nasdaq
$2.32▲ 1.53%vs prev close
🔒 Quotes & buy pressure are MAX onlySee plans
Market cap $179.1MShares out 77.2M sh
Chart
Filings & news by date
Hover (PC) or tap (mobile) a candle to see that day only
Filings
4- 9.4After-hours26.09.05 06:15S-8Offering#●●●
Eledon Pharmaceuticals, Inc.
Eledon Pharmaceuticals has filed a Form S-8 registration statement to register a total of 4,421,000 shares of common stock for issuance under its 2020 Long Term Incentive Plan and a new Stock Option Agreement (Inducement Grant). The registration covers 3,500,000 shares for the incentive plan and 921,000 shares for inducement grants, aimed at compensating employees. This filing formalizes the company's equity-based compensation structure to support talent retention and long-term performance.…more
$2.32+1.53%vs prev closeDetected5m · 30m · 60m · Next dayPLUSView filingShare
- 8.4After-hours26.08.05 06:224Ownership
Eledon Pharmaceuticals, Inc.
Eledon Pharmaceuticals의 내부자인 Gros David-Alexandre C가 2026년 7월 31일 자로 주식 소유 변동을 보고했습니다. 본 공시는 SEC Form 4를 통한 내부자의 지분 변동 사항을 공식적으로 기록한 것입니다.…more
$2.32+1.53%vs prev closeView filingShare - 8.4After-hours26.08.05 06:224Ownership
Eledon Pharmaceuticals, Inc.
엘레돈 파마슈티컬스(Eledon Pharmaceuticals, Inc.)의 내부자인 스티븐 페린(Steven Perrin)이 2026년 7월 31일 자로 주식 소유 현황 변경 보고서인 Form 4를 제출했습니다. 본 공시는 내부자의 지분 변동 사항을 SEC에 공식적으로 보고한 건입니다.…more
$2.32+1.53%vs prev closeView filingShare
3 more filings
Sign up free to unlock the full feed and real-time filing & news alerts.
- ✓Free — no card required
- ✓Full real-time filing & news feed
- ✓Daily Today Report
News
GlobeNewswire- 10.5After-hours26.10.06 05:05#●●●#●●●
Eledon Pharmaceuticals to Present Phase 2 Clinical Results at ASN Kidney Week 2026…more
Eledon Pharmaceuticals announced it will present patient-reported outcomes from its Phase 2 BESTOW trial for tegoprubart at the upcoming ASN Kidney Week 2026. As this is a standard clinical data presentation, the impact on the stock price is expected to be neutral.…more
$2.32+1.53%vs prev closeDetected5m · 30m · 60m · Next dayPLUS
- 9.22Pre-market26.09.22 20:10
●●●●●●●● ●●●●● ●●●●●●
Eledon Pharmaceuticals announced that its kidney transplant rejection prevention candidate, tegoprubart, has been granted FDA Fast Track designation. Following positive long-term Phase 2 results, the company plans to initiate a Phase 3 study in the fourth quarter of 2026.…more
$2.32+1.53%vs prev closeShareBenzinga - 9.22Pre-market26.09.22 20:00
●●●●●●●● ●●●●● ●●●●●●
Eledon Pharmaceuticals announced positive long-term Phase 2 data for its kidney transplant rejection drug, tegoprubart, and secured FDA Fast Track designation. The company plans to initiate Phase 3 trials later this year, though it remains dependent on future financing to support its clinical development.…more
$2.32+1.53%vs prev close
2 more news items
Sign up free to unlock the full feed and real-time filing & news alerts.
- ✓Free — no card required
- ✓Full real-time filing & news feed
- ✓Daily Today Report